ArticleTranslational cancer research2020
Construction of nomograms for nasopharyngeal carcinoma containing primary tumor size and SEER stage.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Machine learning model for predicting recurrence following intensity-modulated radiation therapy in nasopharyngeal carcinoma.World journal of surgical oncology · 2025Article
- Development of a well-defined tool to predict the overall survival in lung cancer patients: an African based cohort.BMC cancer · 2023Article
- Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt present, little attention has been paid to the impact of primary tumor size on the survival of nasopharyngeal carcinoma (NPC). We aimed to construct predictive nomograms for NPC that contain primary tumor size and Surveillance, Epidemiology, and End Results (SEER) stage as factors with the use of a national population-based registry.
methodsA total of 1,574 NPC patients diagnosed between 2004 and 2011 were identified from the SEER database. Univariate and multivariate Cox analysis was used to screen out survival related clinical features. Then, two nomograms of 5-year overall survival (OS) and 5-year cancer-specific survival (CSS) were constructed using the significant clinical features. The concordance index (c-index) and a calibration plot were used to assess the performance of the nomograms. Furthermore, survival analyses were performed by risk score stratification.
resultsAccording to univariate and multivariate analyses, age, race, histology, primary tumor size, SEER stage, radiotherapy and chemotherapy were related to 5-year OS and CSS in NPC. All of these clinical features were included when constructing nomograms. The c-index values were 0.74 and 0.73 for the 5-year OS nomogram in the training cohort and testing cohorts, respectively. For the 5-year CSS nomogram, the c-index values were both 0.73 in the training cohort and testing cohort, respectively. The calibration plots showed that the predicted 5-year OS and CSS outcomes were in good agreement with the observed outcomes. All patients were divided into three groups according to the risk score stratification. Kaplan-Meier survival analyses showed that patients in the low-risk cohort had a greater 5-year survival benefit than patients in the medium-risk and high-risk cohorts (P<0.05).
conclusionsThe predictive nomograms, which contain primary tumor size and SEER stage, can predict the rates of 5-year OS and CSS of NPC patients and can be used as an auxiliary prediction tool for future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.